OptiNose, Inc. (the “Issuer”)
Item 1(b). | Address of the Issuer’s Principal Executive Offices |
1020 Stony Hill Road, Suite 300
Yardley, Pennsylvania 19067
Item 2(a). | Names of Persons Filing |
See Item 2(c) below.
Item 2(b). | Address of the Principal Business Office, or if none, Residence: |
See Item 2(c) below.
This Schedule 13G/A is being filed on behalf of Theodore H. Kruttschnitt, III, a United States citizen.
The address of the principal business office of the reporting person is:
c/o Theodore H. Kruttschnitt, III
3000 Ralston Avenue, Hillsborough, CA 94010
Item 2(d). | Title of Class of Securities |
Common Stock, $0.001 par value (“Common Stock”)
68404V100
Item 3. | If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a(n): |
Not Applicable.
| (a) | Amount beneficially owned: |
See Item 9 on the Cover Page to this Schedule 13G/A.
See Item 11 on the Cover Page to this Schedule 13G/A. The percentage reported herein is based on 82,199,567 shares of Common Stock outstanding as of November 15, 2021, as reported in the Issuer’s Quarterly Report on Form 8-K, filed with the Securities and Exchange Commission on November 18, 2021.
| (c) | Number of shares as to which the Reporting Person has: |
| (i) | Sole power to vote or to direct the vote: |
See Item 5 on the Cover Page to this Schedule 13G/A.
| (ii) | Shared power to vote or to direct the vote: |
See Item 6 on the Cover Page to this Schedule 13G/A.